Roberta Ghidoni

List of Publications by Citations

209 papers	7,765 citations	48 h-index	77 g-index
217 ext. papers	9,720 ext. citations	6.6 avg, IF	5.23 L-index

#	Paper	IF	Citations
209	Progranulin Deficiency Promotes Circuit-Specific Synaptic Pruning by Microglia via Complement Activation. *Cell*, **2016**, 165, 921-35	56.2	378
208	Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis. *Lancet Neurology, The*, **2015**, 14, 253-62	24.1	328
207	Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration. *Neurology*, **2008**, 71, 1235-9	6.5	259
206	Frontotemporal dementia and its subtypes: a genome-wide association study. *Lancet Neurology, The*, **2014**, 13, 686-99	24.1	207
205	TMEM106B regulates progranulin levels and the penetrance of FTLD in GRN mutation carriers. *Neurology*, **2011**, 76, 467-74	6.5	174
204	Neurofilament light chain: a biomarker for genetic frontotemporal dementia. *Annals of Clinical and Translational Neurology*, **2016**, 3, 623-36	5.3	163
203	Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia. *Archives of Neurology*, **2005**, 62, 1734-6		163
202	Microglia convert aggregated amyloid-β into neurotoxic forms through the shedding of microvesicles. *Cell Death and Differentiation*, **2014**, 21, 582-93	12.7	158
201	Digital Detection of Exosomes by Interferometric Imaging. *Scientific Reports*, **2016**, 6, 37246	4.9	139
200	Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference. *Nature Communications*, **2018**, 9, 4273	17.4	125
199	Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. *Nature Reviews Neurology*, **2015**, 11, 41-55	15	116
198	Presenilin mutations linked to familial Alzheimer's disease reduce endoplasmic reticulum and Golgi apparatus calcium levels. *Cell Calcium*, **2006**, 39, 539-50	4	114
197	Longitudinal prognostic value of serum "free" copper in patients with Alzheimer disease. *Neurology* , **2009**, 72, 50-5	6.5	109
196	Patterns of gray matter atrophy in genetic frontotemporal dementia: results from the GENFI study. *Neurobiology of Aging*, **2018**, 62, 191-196	5.6	104
195	Progranulin Leu271LeufsX10 is one of the most common FTLD and CBS associated mutations worldwide. *Neurobiology of Disease*, **2009**, 33, 379-85	7.5	97
194	A novel deletion in progranulin gene is associated with FTDP-17 and CBS. *Neurobiology of Aging*, **2008**, 29, 427-35	5.6	94
193	JNK plays a key role in tau hyperphosphorylation in Alzheimer's disease models. *Journal of Alzheimer's Disease*, **2011**, 26, 315-29	4.3	93

192	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. *Lancet Neurology, The*, **2020**, 19, 145-156	24.1	90
191	Evidence for sub-haplogroup h5 of mitochondrial DNA as a risk factor for late onset Alzheimer's disease. *PLoS ONE*, **2010**, 5, e12037	3.7	87
190	Rare mutations in SQSTM1 modify susceptibility to frontotemporal lobar degeneration. *Acta Neuropathologica*, **2014**, 128, 397-410	14.3	83
189	Immune-related genetic enrichment in frontotemporal dementia: An analysis of genome-wide association studies. *PLoS Medicine*, **2018**, 15, e1002487	11.6	77
188	Optimal plasma progranulin cutoff value for predicting null progranulin mutations in neurodegenerative diseases: a multicenter Italian study. *Neurodegenerative Diseases*, **2012**, 9, 121-7	2.3	77
187	Genetic architecture of sporadic frontotemporal dementia and overlap with Alzheimer's and Parkinson's diseases. *Journal of Neurology, Neurosurgery and Psychiatry*, **2017**, 88, 152-164	5.5	76
186	Value of serum nonceruloplasmin copper for prediction of mild cognitive impairment conversion to Alzheimer disease. *Annals of Neurology*, **2014**, 75, 574-80	9.4	75
185	C9ORF72 repeat expansions in cases with previously identified pathogenic mutations. *Neurology*, **2013**, 81, 1332-41	6.5	75
184	Apolipoprotein E and alpha brain rhythms in mild cognitive impairment: a multicentric electroencephalogram study. *Annals of Neurology*, **2006**, 59, 323-34	9.4	75
183	Cystatin C is released in association with exosomes: a new tool of neuronal communication which is unbalanced in Alzheimer's disease. *Neurobiology of Aging*, **2011**, 32, 1435-42	5.6	71
182	Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. *Lancet Neurology, The*, **2019**, 18, 1103-1111	24.1	68
181	The presenilin 2 M239I mutation associated with familial Alzheimer's disease reduces Ca2+ release from intracellular stores. *Neurobiology of Disease*, **2004**, 15, 269-78	7.5	67
180	TBK1 Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. *Human Mutation*, **2017**, 38, 297-309	4.7	66
179	Is cognitive function linked to serum free copper levels? A cohort study in a normal population. *Clinical Neurophysiology*, **2010**, 121, 502-7	4.3	63
178	Genotype (cystatin C) and EEG phenotype in Alzheimer disease and mild cognitive impairment: a multicentric study. *NeuroImage*, **2006**, 29, 948-64	7.9	63
177	Reduction of Ca2+ stores and capacitative Ca2+ entry is associated with the familial Alzheimer's disease presenilin-2 T122R mutation and anticipates the onset of dementia. *Neurobiology of Disease*, **2005**, 18, 638-48	7.5	62
176	Effects of hormone therapy on brain morphology of healthy postmenopausal women: a Voxel-based morphometry study. *Menopause*, **2006**, 13, 584-91	2.5	62
175	A comprehensive study of the genetic impact of rare variants in SORL1 in European early-onset Alzheimer's disease. *Acta Neuropathologica*, **2016**, 132, 213-224	14.3	62

174	Extracellular vesicles in Alzheimer's disease: friends or foes? Focus on a-vesicle interaction. *International Journal of Molecular Sciences*, **2015**, 16, 4800-13	6.3	61
173	Free copper distinguishes mild cognitive impairment subjects from healthy elderly individuals. *Journal of Alzheimer's Disease*, **2011**, 23, 239-48	4.3	61
172	Mapping the effect of APOE epsilon4 on gray matter loss in Alzheimer's disease in vivo. *NeuroImage*, **2009**, 45, 1090-8	7.9	61
171	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. *Lancet Neurology, The*, **2018**, 17, 548-558	24.1	60
170	TMEM106B p.T185S regulates TMEM106B protein levels: implications for frontotemporal dementia. *Journal of Neurochemistry*, **2013**, 126, 781-91	6	57
169	Alzheimer disease-associated cystatin C variant undergoes impaired secretion. *Neurobiology of Disease*, **2003**, 13, 15-21	7.5	56
168	Exosomes: the Trojan horses of neurodegeneration. *Medical Hypotheses*, **2008**, 70, 1226-7	3.8	55
167	Identification of evolutionarily conserved gene networks mediating neurodegenerative dementia. *Nature Medicine*, **2019**, 25, 152-164	50.5	55
166	Presenilin 1 protein directly interacts with Bcl-2. *Journal of Biological Chemistry*, **1999**, 274, 30764-9	5.4	54
165	Copper dyshomeostasis in Wilson disease and Alzheimer's disease as shown by serum and urine copper indicators. *Journal of Trace Elements in Medicine and Biology*, **2018**, 45, 181-188	4.1	52
164	Diagnostic and prognostic value of serum NfL and p-Tau in frontotemporal lobar degeneration. *Journal of Neurology, Neurosurgery and Psychiatry*, **2020**, 91, 960-967	5.5	51
163	Chromosome 9p21.3 genotype is associated with vascular dementia and Alzheimer's disease. *Neurobiology of Aging*, **2011**, 32, 1231-5	5.6	49
162	Markers of Alzheimer's disease in a population attending a memory clinic. *Alzheimer's and Dementia* , **2009**, 5, 307-17	1.2	49
161	Atypical dementia associated with a novel presenilin-2 mutation. *Annals of Neurology*, **2003**, 54, 832-6	9.4	48
160	Decreased plasma levels of soluble receptor for advanced glycation end products in mild cognitive impairment. *Journal of Neural Transmission*, **2008**, 115, 1047-50	4.3	46
159	Role of hnRNP-A1 and miR-590-3p in neuronal death: genetics and expression analysis in patients with Alzheimer disease and frontotemporal lobar degeneration. *Rejuvenation Research*, **2011**, 14, 275-81	2.6	45
158	SOD1 mRNA expression in sporadic amyotrophic lateral sclerosis. *Neurobiology of Disease*, **2010**, 39, 198-203	7	45
157	Molecular subtypes of Alzheimer's disease. *Scientific Reports*, **2018**, 8, 3269	4.9	44

156	White matter hyperintensities are seen only in mutation carriers in the GENFI cohort. *NeuroImage: Clinical*, **2017**, 15, 171-180	5.3	43
155	Diagnostic accuracy of markers for prodromal Alzheimer disease in independent clinical series. *Alzheimers and Dementia*, **2013**, 9, 677-86	1.2	43
154	Pattern of structural and functional brain abnormalities in asymptomatic granulin mutation carriers. *Alzheimers and Dementia*, **2014**, 10, S354-S363.e1	1.2	42
153	Supporting evidence for using biomarkers in the diagnosis of MCI due to AD. *Journal of Neurology*, **2013**, 260, 640-50	5.5	42
152	Conformational targeting of intracellular A oligomers demonstrates their pathological oligomerization inside the endoplasmic reticulum. *Nature Communications*, **2014**, 5, 3867	17.4	42
151	Cerebrospinal fluid biomarkers in Progranulin mutations carriers. *Journal of Alzheimers Disease*, **2011**, 27, 781-90	4.3	42
150	An APOE haplotype associated with decreased 4 expression increases the risk of late onset Alzheimer disease. *Journal of Alzheimers Disease*, **2011**, 24, 235-45	4.3	42
149	Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia. *Journal of Neurology, Neurosurgery and Psychiatry*, **2020**, 91, 263-270	5.5	40
148	Loss of exosomes in progranulin-associated frontotemporal dementia. *Neurobiology of Aging*, **2016**, 40, 41-49	5.6	40
147	The new Alzheimer criteria in a naturalistic series of patients with mild cognitive impairment. *Journal of Neurology*, **2010**, 257, 2004-14	5.5	38
146	BACE-2 is overexpressed in Down syndrome. *Experimental Neurology*, **2003**, 182, 335-45	5.7	38
145	CXCR4 involvement in neurodegenerative diseases. *Translational Psychiatry*, **2018**, 8, 73	8.6	36
144	Pharmacogenomics in Alzheimer disease: a genome-wide association study of response to cholinesterase inhibitors. *Neurobiology of Aging*, **2013**, 34, 1711.e7-13	5.6	36
143	The SIRT2 polymorphism rs10410544 and risk of Alzheimer disease in two Caucasian case-control cohorts. *Alzheimers and Dementia*, **2013**, 9, 392-9	1.2	36
142	Cerebrospinal fluid biomarkers for Alzheimer disease: the present and the future. *Neurodegenerative Diseases*, **2011**, 8, 413-20	2.3	35
141	Effects of estrogens on cognition and brain morphology: involvement of the cerebellum. *Maturitas*, **2006**, 54, 222-8	5	35
140	Deleterious ABCA7 mutations and transcript rescue mechanisms in early onset Alzheimer disease. *Acta Neuropathologica*, **2017**, 134, 475-487	14.3	34
139	A genome-wide screening and SNPs-to-genes approach to identify novel genetic risk factors associated with frontotemporal dementia. *Neurobiology of Aging*, **2015**, 36, 2904.e13-26	5.6	34

138	Prevalence of TAU mutations in an Italian clinical series of familial frontotemporal patients. *Neuroscience Letters*, **2003**, 338, 85-7	3.3	34
137	C9ORF72 hexanucleotide repeat number in frontotemporal lobar degeneration: a genotype-phenotype correlation study. *Journal of Alzheimer's Disease*, **2014**, 38, 799-808	4.3	33
136	Toward a Glutamate Hypothesis of Frontotemporal Dementia. *Frontiers in Neuroscience*, **2019**, 13, 304	5.1	32
135	Comparison of arterial spin labeling registration strategies in the multi-center GENetic frontotemporal dementia initiative (GENFI). *Journal of Magnetic Resonance Imaging*, **2018**, 47, 131-140	5.6	32
134	Regional atrophy of transcallosal prefrontal connections in cognitively normal APOE epsilon4 carriers. *Journal of Magnetic Resonance Imaging*, **2009**, 29, 1021-6	5.6	32
133	Cognitive reserve and TMEM106B genotype modulate brain damage in presymptomatic frontotemporal dementia: a GENFI study. *Brain*, **2017**, 140, 1784-1791	11.2	31
132	Replication study to confirm the role of CYP2D6 polymorphism rs1080985 on donepezil efficacy in Alzheimer's disease patients. *Journal of Alzheimer's Disease*, **2012**, 30, 745-9	4.3	31
131	Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study. *CNS Drugs*, **2010**, 24, 163-76	6.7	31
130	Tau Rather than TDP-43 Proteins are Potential Cerebrospinal Fluid Biomarkers for Frontotemporal Lobar Degeneration Subtypes: A Pilot Study. *Journal of Alzheimer's Disease*, **2017**, 55, 585-595	4.3	30
129	Progranulin plasma levels predict the presence of GRN mutations in asymptomatic subjects and do not correlate with brain atrophy: results from the GENFI study. *Neurobiology of Aging*, **2018**, 62, 245.e9-245.e12	5.6	30
128	Genetic variability in SQSTM1 and risk of early-onset Alzheimer dementia: a European early-onset dementia consortium study. *Neurobiology of Aging*, **2015**, 36, 2005.e15-22	5.6	29
127	Poly(GP), neurofilament and grey matter deficits in expansion carriers. *Annals of Clinical and Translational Neurology*, **2018**, 5, 583-597	5.3	29
126	Presymptomatic white matter integrity loss in familial frontotemporal dementia in the GENFI cohort: A cross-sectional diffusion tensor imaging study. *Annals of Clinical and Translational Neurology*, **2018**, 5, 1025-1036	5.3	29
125	Blockade of the tumor necrosis factor-related apoptosis inducing ligand death receptor DR5 prevents beta-amyloid neurotoxicity. *Neuropsychopharmacology*, **2007**, 32, 872-80	8.7	29
124	The Italian Brain Normative Archive of structural MR scans: norms for medial temporal atrophy and white matter lesions. *Aging Clinical and Experimental Research*, **2009**, 21, 266-76	4.8	28
123	Homocysteine and electroencephalographic rhythms in Alzheimer disease: a multicentric study. *Neuroscience*, **2007**, 145, 942-54	3.9	28
122	Interaction between tau and alpha-synuclein proteins is impaired in the presence of P301L tau mutation. *Experimental Cell Research*, **2005**, 308, 78-84	4.2	28
121	Rac1 activation links tau hyperphosphorylation and A□dysmetabolism in Alzheimer's disease. *Acta Neuropathologica Communications*, **2018**, 6, 61	7.3	27

120	A novel MAPT mutation associated with the clinical phenotype of progressive nonfluent aphasia. *Journal of Alzheimer's Disease*, **2011**, 26, 19-26	4.3	27
119	GRN variability contributes to sporadic frontotemporal lobar degeneration. *Journal of Alzheimer's Disease*, **2010**, 19, 171-7	4.3	27
118	The H2 MAPT haplotype is associated with familial frontotemporal dementia. *Neurobiology of Disease*, **2006**, 22, 357-62	7.5	27
117	Clinical and biomarker changes in presymptomatic genetic frontotemporal dementia. *Neurobiology of Aging*, **2019**, 76, 133-140	5.6	27
116	New insights into the genetic etiology of Alzheimer's disease and related dementias.. *Nature Genetics*, **2022**,	36.3	27
115	Good gene, bad gene: new APP variant may be both. *Progress in Neurobiology*, **2012**, 99, 281-92	10.9	26
114	Plasma cystatin C and risk of developing Alzheimer's disease in subjects with mild cognitive impairment. *Journal of Alzheimer's Disease*, **2010**, 22, 985-91	4.3	26
113	Optimization protocol for amyloid-beta peptides detection in human cerebrospinal fluid using SELDI TOF MS. *Proteomics - Clinical Applications*, **2010**, 4, 352-7	3.1	26
112	Novel CSF biomarkers in genetic frontotemporal dementia identified by proteomics. *Annals of Clinical and Translational Neurology*, **2019**, 6, 698-707	5.3	25
111	Anti-AMPA GluA3 antibodies in Frontotemporal dementia: a new molecular target. *Scientific Reports*, **2017**, 7, 6723	4.9	25
110	Distinct cerebrospinal fluid amyloid-beta peptide signatures in cognitive decline associated with Alzheimer's disease and schizophrenia. *Electrophoresis*, **2012**, 33, 3738-44	3.6	25
109	Novel T719P AbetaPP mutation unbalances the relative proportion of amyloid-beta peptides. *Journal of Alzheimer's Disease*, **2009**, 18, 295-303	4.3	25
108	Frontotemporal dementia: impact of P301L tau mutation on a healthy carrier. *Journal of Neurology, Neurosurgery and Psychiatry*, **2004**, 75, 1607-10	5.5	25
107	Serum Glial Fibrillary Acidic Protein (GFAP) Is a Marker of Disease Severity in Frontotemporal Lobar Degeneration. *Journal of Alzheimer's Disease*, **2020**, 77, 1129-1141	4.3	25
106	A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. *Brain*, **2018**, 141, 2895-2907	11.2	25
105	Functional network resilience to pathology in presymptomatic genetic frontotemporal dementia. *Neurobiology of Aging*, **2019**, 77, 169-177	5.6	24
104	Cerebral perfusion changes in presymptomatic genetic frontotemporal dementia: a GENFI study. *Brain*, **2019**, 142, 1108-1120	11.2	23
103	MiRNA Profiling in Plasma Neural-Derived Small Extracellular Vesicles from Patients with Alzheimer's Disease. *Cells*, **2020**, 9,	7.9	23

102	Expression of A2V-mutated A in Caenorhabditis elegans results in oligomer formation and toxicity. *Neurobiology of Disease*, **2014**, 62, 521-32	7.5	23
101	Common variants in Alzheimer disease and risk stratification by polygenic risk scores. *Nature Communications*, **2021**, 12, 3417	17.4	23
100	Loss of Neuroprotective Factors in Neurodegenerative Dementias: The End or the Starting Point?. *Frontiers in Neuroscience*, **2017**, 11, 672	5.1	21
99	Losing protein in the brain: the case of progranulin. *Brain Research*, **2012**, 1476, 172-82	3.7	21
98	Alzheimer CSF markers in older schizophrenia patients. *International Journal of Geriatric Psychiatry* , **2011**, 26, 640-8	3.9	21
97	Rare Variants in PLD3 Do Not Affect Risk for Early-Onset Alzheimer Disease in a European Consortium Cohort. *Human Mutation*, **2015**, 36, 1226-35	4.7	20
96	Role of OLR1 and its regulating hsa-miR369-3p in Alzheimer disease: genetics and expression analysis. *Journal of Alzheimers Disease*, **2011**, 26, 787-93	4.3	20
95	The NOS3 G894T (Glu298Asp) polymorphism is a risk factor for frontotemporal lobar degeneration. *European Journal of Neurology*, **2009**, 16, 37-42	6	20
94	Presenilin 2 mutations alter cystatin C trafficking in mouse primary neurons. *Neurobiology of Aging*, **2007**, 28, 371-6	5.6	20
93	Next Generation Sequencing Analysis in Early Onset Dementia Patients. *Journal of Alzheimers Disease*, **2019**, 67, 243-256	4.3	20
92	Pathogenic Huntingtin Repeat Expansions in Patients with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. *Neuron*, **2021**, 109, 448-460.e4	13.9	20
91	Neurodevelopmental disorders: Metallomics studies for the identification of potential biomarkers associated to diagnosis and treatment. *Journal of Trace Elements in Medicine and Biology*, **2020**, 60, 126499	4.1	19
90	Susceptible genes and disease mechanisms identified in frontotemporal dementia and frontotemporal dementia with Amyotrophic Lateral Sclerosis by DNA-methylation and GWAS. *Scientific Reports*, **2017**, 7, 8899	4.9	19
89	The H1 haplotype of the tau gene (MAPT) is associated with mild cognitive impairment. *Journal of Alzheimers Disease*, **2010**, 19, 909-14	4.3	19
88	Circulating progranulin as a biomarker for neurodegenerative diseases. *American Journal of Neurodegenerative Disease*, **2012**, 1, 180-90	2.5	19
87	The inner fluctuations of the brain in presymptomatic Frontotemporal Dementia: The chronnectome fingerprint. *NeuroImage*, **2019**, 189, 645-654	7.9	18
86	Incidence of frontotemporal lobar degeneration in Italy: The Salento-Brescia Registry study. *Neurology*, **2019**, 92, e2355-e2363	6.5	18
85	The Heritability of Frontotemporal Lobar Degeneration: Validation of Pedigree Classification Criteria in a Northern Italy Cohort. *Journal of Alzheimers Disease*, **2018**, 61, 753-760	4.3	18

84	Possible new targets for GPCR modulation: allosteric interactions, plasma membrane domains, intercellular transfer and epigenetic mechanisms. *Journal of Receptor and Signal Transduction Research*, **2011**, 31, 315-31	2.6	18
83	Translational proteomics in Alzheimer's disease and related disorders. *Clinical Biochemistry*, **2013**, 46, 480-6	3.5	17
82	Innovative Biomarkers for Alzheimer's Disease: Focus on the Hidden Disease Biomarkers. *Journal of Alzheimer's Disease*, **2018**, 62, 1507-1518	4.3	16
81	Possible genetic and epigenetic links between human inner speech, schizophrenia and altruism. *Brain Research*, **2012**, 1476, 38-57	3.7	16
80	A novel progranulin mutation causing frontotemporal lobar degeneration with heterogeneous phenotypic expression. *Journal of Alzheimer's Disease*, **2011**, 23, 7-12	4.3	16
79	Progranulin mutations are a common cause of FTLD in Northern Italy. *Alzheimer Disease and Associated Disorders*, **2010**, 24, 308-9	2.5	16
78	Genome Wide Association Study and Next Generation Sequencing: A Glimmer of Light Toward New Possible Horizons in Frontotemporal Dementia Research. *Frontiers in Neuroscience*, **2019**, 13, 506	5.1	15
77	Predictors of comprehensive stimulation program efficacy in patients with cognitive impairment. Clinical practice recommendations. *International Journal of Geriatric Psychiatry*, **2013**, 28, 26-33	3.9	15
76	Early symptoms in symptomatic and preclinical genetic frontotemporal lobar degeneration. *Journal of Neurology, Neurosurgery and Psychiatry*, **2020**, 91, 975-984	5.5	15
75	Estimating the age of the most common Italian GRN mutation: walking back to Canossa times. *Journal of Alzheimer's Disease*, **2013**, 33, 69-76	4.3	14
74	Prevalence of pathogenic mutations in an Italian clinical series of patients with familial dementia. *Current Alzheimer Research*, **2004**, 1, 215-8	3	14
73	Progression of Behavioral Disturbances and Neuropsychiatric Symptoms in Patients With Genetic Frontotemporal Dementia. *JAMA Network Open*, **2021**, 4, e2030194	10.4	14
72	Clinical value of cerebrospinal fluid neurofilament light chain in semantic dementia. *Journal of Neurology, Neurosurgery and Psychiatry*, **2019**, 90, 997-1004	5.5	13
71	Role for ATXN1, ATXN2, and HTT intermediate repeats in frontotemporal dementia and Alzheimer's disease. *Neurobiology of Aging*, **2020**, 87, 139.e1-139.e7	5.6	13
70	Molecular Pathways Bridging Frontotemporal Lobar Degeneration and Psychiatric Disorders. *Frontiers in Aging Neuroscience*, **2016**, 8, 10	5.3	13
69	Genetic Counseling and Testing for Alzheimer's Disease and Frontotemporal Lobar Degeneration: An Italian Consensus Protocol. *Journal of Alzheimer's Disease*, **2016**, 51, 277-91	4.3	13
68	White matter hyperintensities in progranulin-associated frontotemporal dementia: A longitudinal GENFI study. *NeuroImage: Clinical*, **2019**, 24, 102077	5.3	13
67	Rare nonsynonymous variants in SORT1 are associated with increased risk for frontotemporal dementia. *Neurobiology of Aging*, **2018**, 66, 181.e3-181.e10	5.6	12

66	Neuroprotection mediated by cystatin C-loaded extracellular vesicles. *Scientific Reports*, **2019**, 9, 11104	4.9	12
65	A window into the heterogeneity of human cerebrospinal fluid A peptides. *Journal of Biomedicine and Biotechnology*, **2011**, 2011, 697036		12
64	PRNP P39L Variant is a Rare Cause of Frontotemporal Dementia in Italian Population. *Journal of Alzheimer's Disease*, **2016**, 50, 353-7	4.3	12
63	Common and rare TBK1 variants in early-onset Alzheimer disease in a European cohort. *Neurobiology of Aging*, **2018**, 62, 245.e1-245.e7	5.6	12
62	BAG1 is a protective factor for sporadic frontotemporal lobar degeneration but not for Alzheimer's disease. *Journal of Alzheimer's Disease*, **2011**, 23, 701-7	4.3	11
61	HOXA1 A218G polymorphism is associated with smaller cerebellar volume in healthy humans. *Journal of Neuroimaging*, **2009**, 19, 353-8	2.8	11
60	The CST3 B haplotype is associated with frontotemporal lobar degeneration. *European Journal of Neurology*, **2010**, 17, 143-6	6	11
59	Faster Cortical Thinning and Surface Area Loss in Presymptomatic and Symptomatic C9orf72 Repeat Expansion Adult Carriers. *Annals of Neurology*, **2020**, 88, 113-122	9.4	11
58	Combined mass quantitation and phenotyping of intact extracellular vesicles by a microarray platform. *Analytica Chimica Acta*, **2016**, 902, 160-167	6.6	10
57	Inhibition of energy metabolism down-regulates the Alzheimer related presenilin 2 gene. *Journal of Neural Transmission*, **2003**, 110, 1029-39	4.3	10
56	Detection of the presenilin 1 COOH-terminal fragment in the extracellular compartment: a release enhanced by apoptosis. *Experimental Cell Research*, **2001**, 269, 256-65	4.2	10
55	Spatiotemporal analysis for detection of pre-symptomatic shape changes in neurodegenerative diseases: Initial application to the GENFI cohort. *NeuroImage*, **2019**, 188, 282-290	7.9	10
54	The level of 24-Hydroxycholesteryl Esters is an Early Marker of Alzheimer's Disease. *Journal of Alzheimer's Disease*, **2017**, 56, 825-833	4.3	9
53	Mirror Image of the Amyloid- Species in Cerebrospinal Fluid and Cerebral Amyloid in Alzheimer's Disease. *Journal of Alzheimer's Disease*, **2015**, 47, 877-81	4.3	9
52	H1 haplotype of the MAPT gene is associated with lower regional gray matter volume in healthy carriers. *European Journal of Human Genetics*, **2009**, 17, 287-94	5.3	9
51	Apathy in presymptomatic genetic frontotemporal dementia predicts cognitive decline and is driven by structural brain changes. *Alzheimer's and Dementia*, **2021**, 17, 969-983	1.2	9
50	The Missing Heritability of Sporadic Frontotemporal Dementia: New Insights from Rare Variants in Neurodegenerative Candidate Genes. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	8
49	Italian Frontotemporal Dementia Network (FTD Group-SINDEM): sharing clinical and diagnostic procedures in Frontotemporal Dementia in Italy. *Neurological Sciences*, **2015**, 36, 751-7	3.5	8

48	Is KIF24 a genetic risk factor for Frontotemporal Lobar Degeneration?. *Neuroscience Letters*, **2010**, 482, 240-4	3.3	8
47	Effect of the XbaI polymorphism of estrogen receptor alpha on postmenopausal gray matter. *Neuroscience Letters*, **2008**, 434, 304-9	3.3	8
46	Lack of association between MnSOD gene polymorphism and sporadic Alzheimer disease. *Aging Clinical and Experimental Research*, **2005**, 17, 445-8	4.8	8
45	Brain functional network integrity sustains cognitive function despite atrophy in presymptomatic genetic frontotemporal dementia. *Alzheimer and Dementia*, **2021**, 17, 500-514	1.2	8
44	Quantitative Genetics Validates Previous Genetic Variants and Identifies Novel Genetic Players Influencing Alzheimer Disease Cerebrospinal Fluid Biomarkers. *Journal of Alzheimer Disease*, **2018**, 66, 639-652	4.3	8
43	Secretory leukocyte protease inhibitor protein regulates the penetrance of frontotemporal lobar degeneration in progranulin mutation carriers. *Journal of Alzheimer Disease*, **2014**, 38, 533-9	4.3	7
42	Failure to replicate an association of rs5984894 SNP in the PCDH11X gene in a collection of 1,222 Alzheimer disease affected patients. *Journal of Alzheimer Disease*, **2010**, 21, 385-8	4.3	7
41	Copper Imbalance in Alzheimer Disease: Meta-Analysis of Serum, Plasma, and Brain Specimens, and Replication Study Evaluating Gene Variants. *Biomolecules*, **2021**, 11,	5.9	7
40	Altered Expression of Circulating Cdc42 in Frontotemporal Lobar Degeneration. *Journal of Alzheimer Disease*, **2018**, 61, 1477-1483	4.3	6
39	Characterization of Amyloid- Deposits in Bovine Brains. *Journal of Alzheimer Disease*, **2016**, 51, 875-87	4.3	6
38	Genetics and expression analysis of the specificity protein 4 gene (SP4) in patients with Alzheimer disease and frontotemporal lobar degeneration. *Journal of Alzheimer Disease*, **2012**, 31, 537-42	4.3	6
37	Association of blood pressure and genetic background with white matter lesions in patients with mild cognitive impairment. *Journals of Gerontology - Series A Biological Sciences and Medical Sciences*, **2008**, 63, 510-7	6.4	6
36	Areas of intervention for genetic counselling of dementia: cross-cultural comparison between Italians and Americans. *Patient Education and Counseling*, **2006**, 64, 285-93	3.1	6
35	Analysis of alpha-2-macroglobulin-2 allele as a risk factor in Alzheimer disease. *Dementia and Geriatric Cognitive Disorders*, **2001**, 12, 305-8	2.6	6
34	Progranulin Mutations Affects Brain Oscillatory Activity in Fronto-Temporal Dementia. *Frontiers in Aging Neuroscience*, **2016**, 8, 35	5.3	6
33	A Novel Nonsense Angiogenin Mutation is Associated With Alzheimer Disease. *Alzheimer Disease and Associated Disorders*, **2019**, 33, 163-165	2.5	5
32	Genetic variation across RNA metabolism and cell death gene networks is implicated in the semantic variant of primary progressive aphasia. *Scientific Reports*, **2019**, 9, 10854	4.9	5
31	Depletion of Progranulin Reduces GluN2B-Containing NMDA Receptor Density, Tau Phosphorylation, and Dendritic Arborization in Mouse Primary Cortical Neurons. *Journal of Pharmacology and Experimental Therapeutics*, **2017**, 363, 164-175	4.7	5

30	CCL8/MCP-2 association analysis in patients with Alzheimer's disease and frontotemporal lobar degeneration. *Journal of Neurology*, **2009**, 256, 1379-81	5.5	5
29	Presenilin 2 is secreted in mouse primary neurons: a release enhanced by apoptosis. *Mechanisms of Ageing and Development*, **2007**, 128, 350-3	5.6	5
28	, age at onset, and ancestry help discriminate behavioral from language variants in FTLD cohorts. *Neurology*, **2020**, 95, e3288-e3302	6.5	5
27	Plasma Extracellular Vesicle Size and Concentration Are Altered in Alzheimer's Disease, Dementia With Lewy Bodies, and Frontotemporal Dementia. *Frontiers in Cell and Developmental Biology*, **2021** , 9, 667369	5.7	5
26	Serum Copper is not Altered in Frontotemporal Lobar Degeneration. *Journal of Alzheimer's Disease*, **2018**, 63, 1427-1432	4.3	4
25	Tau missing from CSF: a case report. *Journal of Neurology*, **2007**, 254, 107-9	5.5	4
24	Asymptomatic Carriers of Presenilin-1 E318G Variant Show no Cerebrospinal Fluid Biochemical Signs Suggestive of Alzheimer's disease in a Family with Late-onset Dementia. *Current Alzheimer Research*, **2019**, 16, 1-7	3	4
23	Effects of Multiple Genetic Loci on Age at Onset in Frontotemporal Dementia. *Journal of Alzheimer's Disease*, **2017**, 56, 1271-1278	4.3	3
22	Serum C-Peptide, Visfatin, Resistin, and Ghrelin are Altered in Sporadic and GRN-Associated Frontotemporal Lobar Degeneration. *Journal of Alzheimer's Disease*, **2018**, 61, 1053-1060	4.3	3
21	MRI data-driven algorithm for the diagnosis of behavioural variant frontotemporal dementia. *Journal of Neurology, Neurosurgery and Psychiatry*, **2021**,	5.5	3
20	Gene Expression Imputation Across Multiple Tissue Types Provides Insight Into the Genetic Architecture of Frontotemporal Dementia and Its Clinical Subtypes. *Biological Psychiatry*, **2021**, 89, 825-833	7.9	3
19	N-Terminally Truncated and Pyroglutamate-Modified A Forms Are Measurable in Human Cerebrospinal Fluid and Are Potential Markers of Disease Progression in Alzheimer's Disease. *Frontiers in Neuroscience*, **2021**, 15, 708119	5.1	3
18	Genetic variation in APOE, GRN, and TP53 are phenotype modifiers in frontotemporal dementia. *Neurobiology of Aging*, **2021**, 99, 99.e15-99.e22	5.6	3
17	FUS/TLS genetic variability in sporadic frontotemporal lobar degeneration. *Journal of Alzheimer's Disease*, **2010**, 19, 1317-22	4.3	2
16	Modulation of presenilin-1 processing by nitric oxide during apoptosis induced by serum withdrawal and glucose deprivation. *Annals of the New York Academy of Sciences*, **1999**, 893, 294-7	6.5	2
15	Stratifying the Presymptomatic Phase of Genetic Frontotemporal Dementia by Serum NfL and pNfH: A Longitudinal Multicentre Study. *Annals of Neurology*, **2021**,	9.4	2
14	Brain functional network integrity sustains cognitive function despite atrophy in presymptomatic genetic frontotemporal dementia		2
13	Analysis of brain atrophy and local gene expression in genetic frontotemporal dementia		2

12	Late onset neurodegenerative diseases: a theoretical point of view. *Medical Hypotheses*, **2009**, 72, 102	3.8	1
11	Plasma Small Extracellular Vesicles with Complement Alterations in / and Sporadic Frontotemporal Lobar Degeneration.. *Cells*, **2022**, 11,	7.9	1
10	Data-driven staging of genetic frontotemporal dementia using multi-modal MRI.. *Human Brain Mapping*, **2022**,	5.9	1
9	Investigating the Endo-Lysosomal System in Major Neurocognitive Disorders Due to Alzheimer's Disease, Frontotemporal Lobar Degeneration and Lewy Body Disease: Evidence for SORL1 as a Cross-Disease Gene.. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	1
8	The Rise of the GRN C157KfsX97 Mutation in Southern Italy: Going Back to the Fall of the Western Roman Empire. *Journal of Alzheimer's Disease*, **2020**, 78, 387-394	4.3	1
7	Mendelian randomization implies no direct causal association between leukocyte telomere length and amyotrophic lateral sclerosis. *Scientific Reports*, **2020**, 10, 12184	4.9	1
6	Polymorphic Genetic Markers of the GABA Catabolism Pathway in Alzheimer's Disease. *Journal of Alzheimer's Disease*, **2020**, 77, 301-311	4.3	1
5	Exploring Neurofilament Light Chain and Exosomes in the Genetic Forms of Frontotemporal Dementia.. *Frontiers in Neuroscience*, **2022**, 16, 758182	5.1	0
4	Prodromal frontotemporal dementia: clinical features and predictors of progression. *Alzheimer's Research and Therapy*, **2021**, 13, 188	9	0
3	A panel of CSF proteins separates genetic frontotemporal dementia from presymptomatic mutation carriers: a GENFI study. *Molecular Neurodegeneration*, **2021**, 16, 79	19	0
2	Iron Serum Markers Profile in Frontotemporal Lobar Degeneration. *Journal of Alzheimer's Disease*, **2020**, 78, 1373-1380	4.3	0
1	Association of rs3027178 polymorphism in the circadian clock gene PER1 with susceptibility to Alzheimer's disease and longevity in an Italian population.. *GeroScience*, **2021**, 1	8.9	0